Education
About Us
Working with TipRanks
Follow Us
Orasure (OSUR)
:OSUR
Top Page
Orasure Technologies
(NASDAQ:OSUR)
Rating:54Neutral
Price Target:
$3.00
▼(-3.85% Downside)
Orasure Technologies (OSUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$233.38M
Dividend YieldN/A
Average Volume (3M)718.26K
Price to Earnings (P/E)25.3
Beta (1Y)0.60
Revenue Growth-46.95%
EPS Growth-237.44%
CountryUS
Employees501
SectorHealthcare
Sector Strength38
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.26
Shares Outstanding74,800,130
10 Day Avg. Volume520,922
30 Day Avg. Volume718,258
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.65
Price to Sales (P/S)1.45
P/FCF Ratio11.40
Enterprise Value/Market Cap0.08
Enterprise Value/Revenue0.49
Enterprise Value/Gross Profit0.44
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$3.00Price Target Upside-3.85% Downside
Rating ConsensusHold
Number of Analyst Covering2
Orasure Technologies Business Overview & Revenue Model
Company DescriptionOraSure Technologies, Inc. is a leader in the development, manufacture, and distribution of oral fluid diagnostic and collection devices. The company operates primarily in the healthcare sector, providing innovative solutions that address critical health needs, including infectious disease testing, substance abuse testing, and DNA collection. OraSure's core products include rapid diagnostic testing kits for HIV, Hepatitis C, and other infectious diseases, as well as microbiome and genomics services through its subsidiaries.
How the Company Makes MoneyOraSure Technologies generates revenue primarily through the sale of its diagnostic products and services. The company markets its rapid diagnostic test kits to healthcare providers, government agencies, and consumers. A significant portion of its earnings comes from its flagship products like the OraQuick HIV and OraQuick HCV tests, which are widely used for public health screening. Additionally, OraSure earns revenue from its DNA Genotek subsidiary, which provides sample collection kits for genetic research and testing. The company's business model is further supported by strategic partnerships with government health organizations and research institutions, as well as licensing agreements and collaborations with other healthcare companies.
Orasure Technologies Earnings Call Summary
Earnings Call Date:Aug 05, 2025
(Q1-2025)
| % Change Since: 0.00%|
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments and challenges. While the company reported strong diagnostics revenue growth and successful integration of Sherlock Biosciences, it faced significant headwinds from funding uncertainties and disruptions in the Sample Management Solutions segment. The overall sentiment is balanced with positive steps towards innovation and growth, countered by challenges in funding and customer disruptions.Q1-2025 Updates
Positive Updates
Core Revenue Performance
Q1 core revenue was $29.5 million, above the midpoint of the guidance range, and flat year-over-year after adjusting for the exit from the risk assessment testing business.
Diagnostics Revenue Growth
Diagnostics revenue grew 8% year-over-year, driven by international business and initial orders for WHO PQ listed hepatitis C self-test.
Successful Integration of Sherlock Biosciences
Integration of Sherlock Biosciences is progressing well, contributing to OTI's product pipeline with molecular diagnostics innovation.
Stock Repurchase Program
Board authorized the repurchase of up to $40 million of common stock over the next two years, funded from cash on hand.
International Business Stability
International Diagnostics business remains steady despite funding uncertainties, with growth driven by hepatitis C self-test orders.
New Product Launches
Planned product launches include microbiome extraction kits, blood proteomics sample stabilization, and entrance into the small volume self-collected blood segment.
Negative Updates
Sample Management Solutions Revenue Decline
SMS revenue decreased 16% year-over-year due to disruption at a large customer in the Consumer Genomics segment.
U.S. Diagnostics Headwinds
Elevated uncertainty in the U.S. due to potential budget cuts and staffing reductions at public health organizations.
PEPFAR and USAID Funding Disruption
Disruption in USAID and PEPFAR sponsored programs contributed to revenue headwinds, although less severe than initially expected.
Together Take Me Home Program Ending
The program is scheduled to end in September 2025 due to funding impacts, contributing to a $4 million revenue headwind for the year.
Uncertain Consumer Genomics Partnership
Significant disruption from a major consumer genomics customer with no expected revenue in Q2 and uncertain future ordering potential.
Company Guidance
During the OraSure Technologies 2025 First Quarter Earnings Call, the company provided guidance for the second quarter, projecting total revenue of $28.5 million to $32.5 million and core revenue of $28 million to $32 million, excluding COVID-19 and risk assessment testing revenues, which are expected to contribute approximately $5 million. The company anticipates its gross margin percentage to be flat or slightly up compared to the first quarter, with potential expansion in the second half of the year driven by increased volumes and efficiencies from automation and site consolidation. Operating expenses in Q2 are expected to include core expenses in the low $20 million range, plus $10 million in innovation investments, of which $7 million to $8 million are related to the Sherlock acquisition. The company also announced a $40 million stock repurchase program over the next two years, funded from cash on hand, aligning with their capital deployment strategy.Orasure Technologies Financial Statement Overview
Summary
Orasure Technologies faces financial challenges with declining revenues and profitability, as evidenced by a net loss and negative EBIT and EBITDA margins. Despite a strong balance sheet with low leverage, negative profitability and cash flow issues highlight operational inefficiencies.Income Statement
Orasure Technologies has faced challenges in its income statement with declining revenues and profitability. The TTM (Trailing-Twelve-Months) shows a net loss with negative EBIT and EBITDA margins, indicating operational inefficiencies. Revenue growth has been erratic, with recent declines, suggesting volatility in sales performance.48
Neutral
Balance Sheet
The balance sheet of Orasure Technologies is relatively strong, with a high equity ratio and low debt levels. The company's debt-to-equity ratio is low, implying low financial leverage and risk. However, despite strong equity, the return on equity is negative, highlighting the impact of ongoing losses.72
Positive
Cash Flow
Cash flow analysis reveals a mixed picture. The company has generated positive operating cash flow in the TTM, but free cash flow has turned negative due to capital expenditures. The free cash flow to net income ratio indicates challenges in converting earnings to cash, suggesting operational inefficiencies.55
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.67M | 185.83M | 405.47M | 387.48M | 233.67M | 171.72M |
| Gross Profit | 43.19M | 79.39M | 179.42M | 147.64M | 117.60M | 101.87M |
| EBITDA | -31.43M | -5.13M | 64.35M | 10.29M | 9.00K | 3.44M |
| Net Income | -51.03M | -19.50M | 53.66M | -17.93M | -23.00M | -14.92M |
Balance Sheet | ||||||
| Total Assets | 445.04K | 479.66M | 482.85M | 444.71M | 460.99M | 454.47M |
| Cash, Cash Equivalents and Short-Term Investments | 234.58K | 267.76M | 290.41M | 110.85M | 153.04M | 209.40M |
| Total Debt | 0.00 | 14.60M | 13.50M | 12.55M | 12.27M | 6.13M |
| Total Liabilities | 64.31M | 69.32M | 52.17M | 81.08M | 80.46M | 55.90M |
| Stockholders Equity | 380.72M | 410.34M | 430.67M | 363.62M | 380.53M | 398.57M |
Cash Flow | ||||||
| Free Cash Flow | 12.16M | 23.58M | 131.28M | -111.11M | -83.50M | -23.12M |
| Operating Cash Flow | 12.76M | 27.37M | 141.58M | -47.20M | -35.38M | 5.81M |
| Investing Cash Flow | 273.00K | -39.03M | 66.15M | 21.09M | -5.50M | -14.03M |
| Financing Cash Flow | -7.59M | -4.18M | -3.02M | -3.83M | -2.82M | 92.48M |
Orasure Technologies Technical Analysis
Negative
3.12
Price Trends
3.03
Positive
3.03
Positive
3.44
Negative
Market Momentum
0.03
Positive
48.62
Neutral
17.88
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Negative. The current price of 3.12 is below the 20-day moving average (MA) of 3.20, above the 50-day MA of 3.03, and below the 200-day MA of 3.44, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 48.62 is Neutral, neither overbought nor oversold. The STOCH value of 17.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OSUR.
Orasure Technologies Risk Analysis
Orasure Technologies disclosed 66 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orasure Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $178.49M | 14.70 | 10.39% | 2.21% | -16.64% | ― | |
75 Outperform | $147.04M | 16.11 | 28.29% | ― | 29.65% | 131.78% | |
61 Neutral | $202.16M | ― | -179.82% | ― | 1.50% | -20.00% | |
58 Neutral | $151.34M | ― | -29.87% | ― | 19.65% | 60.28% | |
54 Neutral | $233.38M | 25.27 | -7.77% | ― | -46.95% | -237.44% | |
51 Neutral | $7.39B | 0.81 | -66.42% | 2.36% | 16.64% | -0.07% | |
44 Neutral | $217.93M | ― | -28.58% | ― | 34.65% | -128.56% |
* Healthcare Sector Average
Performance Comparison
OSUR
Orasure Technologies
3.12
-1.47
-32.03%
PDEX
Pro-Dex
45.09
25.45
129.58%
STXS
Stereotaxis
2.24
0.39
21.08%
UTMD
Utah Medical Products
56.84
-8.78
-13.38%
KRMD
REPRO-MED Systems
3.28
0.80
32.26%
SMTI
Sanara MedTech
24.52
-3.38
-12.11%
Orasure Technologies Corporate Events
Business Operations and StrategyFinancial Disclosures
OraSure Technologies Reports 43% Revenue Decline in Q2 2025
Negative
Aug 5, 2025
On August 5, 2025, OraSure Technologies announced its financial results for the quarter ended June 30, 2025. The company reported a decrease in total net revenues by 43% compared to the same period in 2024, with significant declines in molecular services and COVID-19 related revenues. Despite the revenue drop, OraSure is focused on expanding its product portfolio and commercial reach, with plans to launch new products and leverage its strong balance sheet for future growth.
The most recent analyst rating on (OSUR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.
Shareholder MeetingsBusiness Operations and Strategy
OraSure Technologies Approves Stock Plan Amendment at Annual Meeting
Neutral
May 14, 2025
On May 14, 2025, OraSure Technologies, Inc. held its Annual Meeting of Stockholders, where an amendment to the 2000 Stock Award Plan was approved, increasing the number of shares authorized for grant by 6,000,000 shares. The meeting also included the election of three Class I Directors, the ratification of Grant Thornton LLP as the independent registered public accounting firm for 2025, and an advisory vote on executive compensation, reflecting key governance and operational decisions impacting the company’s future direction.
The most recent analyst rating on (OSUR) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.
Executive/Board ChangesBusiness Operations and Strategy
OraSure Technologies Announces CPO Resignation
Neutral
May 9, 2025
On May 8, 2025, Kathleen G. Weber announced her resignation as Chief Product Officer of OraSure Technologies, effective June 30, 2025. Her resignation, considered as ‘Good Reason,’ entitles her to severance benefits as per her employment agreement. This change in leadership may impact the company’s operations and strategic direction.
Stock BuybackBusiness Operations and StrategyFinancial Disclosures
OraSure Technologies Reports Q1 2025 Revenue Decline
Negative
May 7, 2025
On May 7, 2025, OraSure Technologies announced its financial results for the first quarter of 2025, revealing a 45% decrease in total net revenues compared to the same period in 2024, primarily due to a decline in COVID-19 revenues. Despite the revenue drop, the company is focusing on expanding its product portfolio and strengthening customer relationships, with a $40 million stock repurchase program authorized to deliver shareholder value.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.